BGB-A317-309

Active, not recruiting

Tislelizumab Combined With Chemotherapy Versus Chemotherapy Alone in Recurrent or Metastatic Nasopharyngeal Cancer

Beigene Study ID info

BGB-A317-309

ClinicalTrials.gov ID info

China Drug Trials ID info

CTR20182534

Study Overview

Sex: All

Age: 18 Years / 75 Years

No Study Documents

Study Overview

Sex: All

Age: 18 Years / 75 Years

No Study Documents